Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Nature

Volumn 560, Issue 7718, 2018, Pages 382-386

  Chen, Gang ^a   Huang, Alexander C ^b   Zhang, Wei ^a,c   Zhang, Gao ^d   Wu, Min ^a   Xu, Wei ^b   Yu, Zili ^c   Yang, Jiegang ^a,c   Wang, Beike ^a,c   Sun, Honghong ^e   Xia, Houfu ^c   Man, Qiwen ^c   Zhong, Wenqun ^a,c   Antelo, Leonardo F ^b   Wu, Bin ^a   Xiong, Xuepeng ^c   Liu, Xiaoming ^e   Guan, Lei ^a,f   Li, Ting ^e,f   Liu, Shujing ^e   Yang, Ruifeng ^e   Lu, Youtao ^a   Dong, Liyun ^e   McGettigan, Suzanne ^b   Somasundaram, Rajasekharan ^d   Radhakrishnan, Ravi ^g   Mills, Gordon ^h   Lu, Yiling ^h   Kim, Junhyong ^a   Chen, Youhai H ^e   Dong, Haidong ⁱ   Zhao, Yifang ^c   Karakousis, Giorgos C ^e   Mitchell, Tara C ^b   Schuchter, Lynn M ^b   Herlyn, Meenhard ^d   Wherry, E John ^e   Xu, Xiaowei ^e   Guo, Wei ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WUHAN UNIVERSITY   (China)

^d WISTAR INSTITUTE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f XI'AN JIAOTONG UNIVERSITY   (China)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LETTER; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG SCREENING; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MELANOMA; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE PROGRESSION; EXOSOMES; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; MELANOMA; MICE; MICE, NUDE; NEOPLASM METASTASIS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85051485029     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-018-0392-8     Document Type: Article

References (32)

1. Dong, H. et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
2. Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015).
3. Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).
4. Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. J. Am. Med. Assoc. 315, 1600–1609 (2016).
5. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
6. Becker, A. et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30, 836–848 (2016).
7. Kalluri, R. The biology and function of exosomes in cancer. J. Clin. Invest. 126, 1208–1215 (2016).
8. Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195–208 (2014).
9. Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 30, 3.22.1–3.22.29 (2006).
10. Colombo, M., Raposo, G. & Thery, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014).
11. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012).
12. Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177–182 (2015).
13. Tibes, R. et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512–2521 (2006).
14. Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Reports 19, 1189–1201 (2017).
15. Schmidt, O. & Teis, D. The ESCRT machinery. Curr. Biol. 22, R116–R120 (2012).
16. Ostrowski, M. et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–30 (2010).
17. Zhou, J. et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol. Res. 5, 480–492 (2017).
18. + exosomes in plasma of head and neck cancer patients. Clin. Cancer Res. 24, 896–905 (2018).
19. Ludwig, S. et al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin. Cancer Res. 23, 4843–4854 (2017).
20. Ricklefs, F. L. et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 4, eaar2766 (2018).
21. Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).
22. Kim, J. W. et al. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 11, 1010–1020 (2005).
23. + responder cells by Fas-mediated apoptosis. J. Immunol. 182, 1469–1480 (2009).
24. + T lymphocytes. J. Immunol. 183, 3720–3730 (2009).
25. Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423–1427 (2017).
26. Hui, E. et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355, 1428–1433 (2017).
27. Shin, D. S. et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 7, 188–201 (2017).
28. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
29. Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).
30. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
31. Nishino, M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936–3943 (2013).
32. Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17–27 (1994).